Anaplastic and poorly differentiated thyroid carcinoma: Therapeutic strategies and treatment outcome of 52 consecutive patients

Oncology

Volumn 79, Issue 5-6, 2011, Pages 400-408

  Siironen, P ^a   Hagstrom J ^b   Maenpaa H O ^a   Louhimo, J ^a   Heikkila A ^b   Heiskanen, I ^a   Arola, J ^b   Haglund, C ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Anaplastic thyroid carcinoma; Poorly differentiated thyroid carcinoma

Indexed keywords

DOXORUBICIN; KI 67 ANTIGEN; PACLITAXEL; PROTEIN P53; RADIOACTIVE IODINE;

ADULT; AGED; ANAPLASTIC THYROID CARCINOMA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DISTANT METASTASIS; ELECTIVE SURGERY; EMERGENCY SURGERY; FEMALE; GENDER; GROUPS BY AGE; HEART METASTASIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LOBECTOMY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; SPLEEN; SURVIVAL TIME; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; VOCAL CORD PARALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 79953196179     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322640     Document Type: Article

References (33)

1. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A: Anaplastic thyroid carcinoma: treatment outcome and prognostic factors. Cancer 2005; 103: 1330-1335. (Pubitemid 40410726)
2. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR: Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130: 1028-1034. (Pubitemid 34014569)
3. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A: Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 2001; 25: 617-622. (Pubitemid 32441436)
4. Besic N, Hocevar M, Zgajnar J, Pogacnik A, Grazio-Frkovic S, Auersperg M: Prognostic factors in anaplastic carcinoma of the thyroid: a multivariate survival analysis of 188 patients. Langenbecks Arch Surg 2005; 390: 203-208. (Pubitemid 40884229)
5. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, Grimelius L, Lundell G, Wallin G: Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 1998; 22: 725-730. (Pubitemid 28277869)
6. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J: Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007; 31: 1256-1264. (Pubitemid 47207131)
7. Carcangiu ML, Zampi G, Rosai J: Poorly differentiated ('insular') thyroid carcinoma: A reinterpretation of Langhans' 'wuchernde Struma' Am J Surg Pathol 1984; 8: 655-668. (Pubitemid 14068779)
8. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA: Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 2006; 106: 1286-1295. (Pubitemid 43363905)
9. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001; 91: 2335-2342. (Pubitemid 32552820)
10. Brignardello E, Gallo M, Baldi I, Palestini N, Piovesan A, Grossi E, Ciccone G, Boccuzzi G: Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 2007; 156: 425-430. (Pubitemid 46672642)
11. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC: Multimodality treatment for anaplastic thyroid carcinoma: treatment outcome in 75 patients. Radiother Oncol 2009; 92: 100-104.
12. Lin JD, Chao TC, Hsueh C: Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas. Clin Endocrinol (Oxf) 2007; 66: 224-228. (Pubitemid 46096142)
13. Kim TY, Kim KW, Jung TS, Kim JM, Kim SW, Chung KW, Kim EY, Gong G, Oh YL, Cho SY, Yi KH, Kim WB, Park do J, Chung JH, Cho BY, Shong YK: Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck 2007; 29: 765-772. (Pubitemid 47265532)
14. Chen J, Tward JD, Shrieve DC, Hitchcock YJ: Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 2008; 31: 460-464.
15. Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A, Iwasaki H, Ito K: The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002; 131: 245-248. (Pubitemid 34229776)
16. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, Torchio B, Papotti MG: Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 2004; 100: 950-957. (Pubitemid 38222855)
17. Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW: An evidence-based review of poorly differentiated thyroid cancer. World J Surg 2007; 31: 934-945. (Pubitemid 46716789)
18. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ: The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002; 9: 57-64. (Pubitemid 34262898)
19. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL, Wallin G: Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002; 86: 1848-1853.
20. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J: Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 2006; 107: 1786-1792. (Pubitemid 44582947)
21. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D: Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991; 67: 564-566.
22. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56: 2155-2160. (Pubitemid 16236586)
23. Kim JH, Leeper RD: Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy: A new approach. Cancer 1983; 52: 954-957. (Pubitemid 13050754)
24. Simpson WJ: Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980; 23: 25-27. (Pubitemid 10159897)
25. Ain KB, Egorin MJ, DeSimone PA: Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-sixhour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10: 587-594. (Pubitemid 30670619)
26. Ain KB, Tofiq S, Taylor KD: Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 1996; 81: 3650-3653. (Pubitemid 26339932)
27. Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A: Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 2000; 60: 650-656. (Pubitemid 30094563)
28. Xu G, Pan J, Martin C, Yeung SC: Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 1769-1777. (Pubitemid 32374936)
29. Yang HL, Pan JX, Sun L, Yeung SC: p21 Waf- 1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003; 88: 763-772. (Pubitemid 36207820)
30. Pan J, Xu G, Yeung SC: Cytochrome c release is upstream to activation of caspase-9, caspase- 8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab 2001; 86: 4731-4740. (Pubitemid 33020513)
31. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA: Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer 1990; 66: 321-330. (Pubitemid 20205915)
32. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA, Timiryasova T, Chen N, Shah JP, Szalay AA, Fong Y, Wong RJ: Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 2007; 142: 976-983; discussion 976-983. (Pubitemid 350193250)
33. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, Fong Y, Wong RJ: Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab 2008; 93: 4403-4407. (Pubitemid 352789538)